Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension

B. L. Pilmer, J. A. Green, Edward A Panacek, W. J. Elliot, M. B. Murphy, W. Rutherford, A. R. Nara

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) ≥ 120 mm Hg were randomized in a single- blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP). Fenoldopam mesylate and NTP infusion rates began at 0.1 μg/kg/minute and 0.5 μg/kg/minute, respectively and were titrated to achieve a goal DBP of between 95 and 110 mm Hg; or a reduction of at least 40 mm Hg if the baseline DBP was > 150 mm Hg. Fenoldopam mesylate (n = 15) reduced blood pressure from 217/145 ± 6/5 to 187/112 ± 6/3 mm Hg (P < .001) at an average infusion rate of 0.5 ± 0.1 μg/kg/minute. The average time to achieve goal DBP with FNP was 1.5 ± 1.4 hours. Nitroprusside (n = 18) reduced blood pressure from 210/136 ± 5/2 to 172/103 ± 6/2 mm Hg (P < .001) at an average infusion rate of 1.2 ± .24 μg/kg/minute. Nitroprusside response time averaged 2 ± 2.5 hours. There was no significant difference between the magnitude of effect seen with either FNP or NTP; nor was there any difference observed in the adverse effect rates of the two agents. Fenoldopam mesylate and NTP demonstrate similar overall efficacy in the treatment of severe systemic hypertension.

Original languageEnglish (US)
Pages (from-to)549-553
Number of pages5
JournalJournal of Clinical Pharmacology
Volume33
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Fenoldopam
Nitroprusside
Blood Pressure
Hypertension
Reaction Time

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pilmer, B. L., Green, J. A., Panacek, E. A., Elliot, W. J., Murphy, M. B., Rutherford, W., & Nara, A. R. (1993). Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. Journal of Clinical Pharmacology, 33(6), 549-553.

Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. / Pilmer, B. L.; Green, J. A.; Panacek, Edward A; Elliot, W. J.; Murphy, M. B.; Rutherford, W.; Nara, A. R.

In: Journal of Clinical Pharmacology, Vol. 33, No. 6, 1993, p. 549-553.

Research output: Contribution to journalArticle

Pilmer, BL, Green, JA, Panacek, EA, Elliot, WJ, Murphy, MB, Rutherford, W & Nara, AR 1993, 'Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension', Journal of Clinical Pharmacology, vol. 33, no. 6, pp. 549-553.
Pilmer, B. L. ; Green, J. A. ; Panacek, Edward A ; Elliot, W. J. ; Murphy, M. B. ; Rutherford, W. ; Nara, A. R. / Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. In: Journal of Clinical Pharmacology. 1993 ; Vol. 33, No. 6. pp. 549-553.
@article{647a11631f7141239c014e86abb4dc01,
title = "Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension",
abstract = "Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) ≥ 120 mm Hg were randomized in a single- blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP). Fenoldopam mesylate and NTP infusion rates began at 0.1 μg/kg/minute and 0.5 μg/kg/minute, respectively and were titrated to achieve a goal DBP of between 95 and 110 mm Hg; or a reduction of at least 40 mm Hg if the baseline DBP was > 150 mm Hg. Fenoldopam mesylate (n = 15) reduced blood pressure from 217/145 ± 6/5 to 187/112 ± 6/3 mm Hg (P < .001) at an average infusion rate of 0.5 ± 0.1 μg/kg/minute. The average time to achieve goal DBP with FNP was 1.5 ± 1.4 hours. Nitroprusside (n = 18) reduced blood pressure from 210/136 ± 5/2 to 172/103 ± 6/2 mm Hg (P < .001) at an average infusion rate of 1.2 ± .24 μg/kg/minute. Nitroprusside response time averaged 2 ± 2.5 hours. There was no significant difference between the magnitude of effect seen with either FNP or NTP; nor was there any difference observed in the adverse effect rates of the two agents. Fenoldopam mesylate and NTP demonstrate similar overall efficacy in the treatment of severe systemic hypertension.",
author = "Pilmer, {B. L.} and Green, {J. A.} and Panacek, {Edward A} and Elliot, {W. J.} and Murphy, {M. B.} and W. Rutherford and Nara, {A. R.}",
year = "1993",
language = "English (US)",
volume = "33",
pages = "549--553",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension

AU - Pilmer, B. L.

AU - Green, J. A.

AU - Panacek, Edward A

AU - Elliot, W. J.

AU - Murphy, M. B.

AU - Rutherford, W.

AU - Nara, A. R.

PY - 1993

Y1 - 1993

N2 - Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) ≥ 120 mm Hg were randomized in a single- blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP). Fenoldopam mesylate and NTP infusion rates began at 0.1 μg/kg/minute and 0.5 μg/kg/minute, respectively and were titrated to achieve a goal DBP of between 95 and 110 mm Hg; or a reduction of at least 40 mm Hg if the baseline DBP was > 150 mm Hg. Fenoldopam mesylate (n = 15) reduced blood pressure from 217/145 ± 6/5 to 187/112 ± 6/3 mm Hg (P < .001) at an average infusion rate of 0.5 ± 0.1 μg/kg/minute. The average time to achieve goal DBP with FNP was 1.5 ± 1.4 hours. Nitroprusside (n = 18) reduced blood pressure from 210/136 ± 5/2 to 172/103 ± 6/2 mm Hg (P < .001) at an average infusion rate of 1.2 ± .24 μg/kg/minute. Nitroprusside response time averaged 2 ± 2.5 hours. There was no significant difference between the magnitude of effect seen with either FNP or NTP; nor was there any difference observed in the adverse effect rates of the two agents. Fenoldopam mesylate and NTP demonstrate similar overall efficacy in the treatment of severe systemic hypertension.

AB - Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) ≥ 120 mm Hg were randomized in a single- blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP). Fenoldopam mesylate and NTP infusion rates began at 0.1 μg/kg/minute and 0.5 μg/kg/minute, respectively and were titrated to achieve a goal DBP of between 95 and 110 mm Hg; or a reduction of at least 40 mm Hg if the baseline DBP was > 150 mm Hg. Fenoldopam mesylate (n = 15) reduced blood pressure from 217/145 ± 6/5 to 187/112 ± 6/3 mm Hg (P < .001) at an average infusion rate of 0.5 ± 0.1 μg/kg/minute. The average time to achieve goal DBP with FNP was 1.5 ± 1.4 hours. Nitroprusside (n = 18) reduced blood pressure from 210/136 ± 5/2 to 172/103 ± 6/2 mm Hg (P < .001) at an average infusion rate of 1.2 ± .24 μg/kg/minute. Nitroprusside response time averaged 2 ± 2.5 hours. There was no significant difference between the magnitude of effect seen with either FNP or NTP; nor was there any difference observed in the adverse effect rates of the two agents. Fenoldopam mesylate and NTP demonstrate similar overall efficacy in the treatment of severe systemic hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0027164047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027164047&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 549

EP - 553

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 6

ER -